Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity

AIDS

Volumn 12, Issue 15, 1998, Pages 1973-1981

  Birk, Markus ^a   Flock, Jan Ingmar ^a   Sönnerborg, Anders ^a   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HIV 1; Immune response; p17 protein; Quasispecies

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; HAPLOTYPE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; VIRUS GENE;

EID: 0032558681     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00008     Document Type: Article

References (21)

1. Preston BD, Poiesz BJ, Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988, 242:1168-1171.
2. Wolinsky SM, Korber BT, Neumann AU, et al.: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996, 272:537-542.
3. Karlsson A, Lindback S, Gaines H, Sonnerborg A: Characterization of the viral population during primary HIV-1 infection. AIDS 1998, 12:839-847.
4. Rodrigo AG, Mullins JI: Human immunodeficiency virus type 1 molecular evolution and the measure of selection. AIDS Res Hum Retroviruses 1996, 12:1681-1685.
5. Cao HY, Kanki P, Sankale JL, et al.: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol 1997, 71:8615-8623.
6. Sipsas NV, Kalams SA, Irocha A, et al.: Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J Clin Invest 1997, 99:752-762.
7. Phillips RE, Rowland-Jones S, Nixon DF, et al.: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991, 354:453-459.
8. Brostrom C, Sonnerborg A, Sallberg M: HIV-1 infected patients with no disease progression display a maintained high avidity antibody production to autologous V3 sequences. J Infect Dis 1995, 172:897-898.
9. Weiner AJ, Erickson AI , Kansopon J, et al.: Persistent hepatitis C virus infection in an infected chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995, 92:2755-2759.
10. Windhagen A, Schloz C, Hollsberg P, Fukaura H, Sette P, Hafler DA: Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995, 2:373-380.
11. Birk M, Vahlne A, Sonnerborg A, Sallberg M: Non-synonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules. AIDS Res Hum Retroviruses 1998, 14:241-248.
12. Yoshimura FK, Diem K, Gerald H, Learn I, Riddell S, Corey L: Intra patient variation of the gag gene of human immunodeficiency virus type 1 plasma virions. J Virol 1996, 70:8879-8887.
13. Metha SU, Rupprecht KR, Hunt JC, et al.: Prevalence of antibodies to the core protein p17, a serological marker during HIV-1 infection. AIDS Res Hum Retroviruses 1990, 6:443-454.
14. Weber J, Cheinsong-Popov R, Callow D, et al.: Immunogenicity of yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in health volunteers. Vaccine 1995, 13:831-834.
15. Zhang ZX, Chen M, Sonnerborg A, Weiland O, Sallberg M: Distinguishing acute from symptomatic chronic hepatitis C virus (HCV) infection by site-directed serology of the HCV structural proteins. J Infect Dis 1995, 171:1356-1359.
16. Stevens TL, Bossie A, Sanders VM, et al.: Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
17. Germann T, Bongartz M, Dlugonska H, et al.: Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995, 25:823-829.
18. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996, 70:427-444.
19. Cichutek K, Merget H, Norley S, et al.: Development of a quasispecies of human immunodeficiency virus type 1 in vivo. Proc Natl Acad Sci USA 1992, 89:7365-7369.
20. Zhang ZX, Chen M, Hultgren C, Birkett A, Milich DR, Sallberg M: Immune responses to the hepatitis C virus NS4a are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex. J Gen Virol 1997, 78:2735-2746.
21. Connor RI, Korber BTM, Graham BS, et al.: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines [review]. J Virol 1998, 72:1552-1576.